15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Immix Biopharma Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $15.00 to $27.00, a moderate spread. The average target of $20.71 sits 145% above the current $8.44. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.84 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Immix Biopharma Inc.
As of Jul, 7 of 7 firms rate IMMX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMMX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.22 – $-0.14 · 7 analysts · -27% YoY
Next period, 7 analysts expect Immix Biopharma Inc to earn $-0.18 a share (range $-0.22 – $-0.14), versus $-0.24 a year earlier. Full-year consensus is $-0.70, growing to $-0.84 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $37.6M next year.
Top analysts covering Immix Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMMX.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$20.00+137.0% to target
Overall win rate
38%
+ Follow
#2
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$27.00+219.9% to target
Overall win rate
41%
+ Follow
#3
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$23.00+172.5% to target
Overall win rate
33%
+ Follow
#4
Gil Blum
Needham · Rank #298
Buy
$21.00+148.8% to target
Overall win rate
24%
+ Follow
#5
Graig Suvannavejh
Mizuho
Buy
$15.00+77.7% to target
Coverage
—
+ Follow
IMMX stock forecast FAQ
What is IMMX's average 12-month price target?+
The 6 analysts with a live target average $20.71 for Immix Biopharma Inc over the next 12 months, ranging from a $27.00 high to a $15.00 low.
Is IMMX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMMX?+
The Street-high target is $27.00 (B of A Securities), and the Street-low is $15.00 (Mizuho). The average of all 6 active targets is $20.71.
How many Wall Street analysts cover IMMX?+
7 analysts have an active rating on Immix Biopharma Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMMX?+
Among analysts who currently cover IMMX, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Buy with a $20.00 target.
What is Immix Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.22 – $-0.14) across 7 analysts. Full-year EPS is projected at $-0.70, rising to $-0.84 the following year.
How much revenue is Immix Biopharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $37.6M next year.
Have analysts been upgrading or downgrading IMMX lately?+
As of Jul, 7 of 7 firms rate IMMX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMMX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
